AMNEAL PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $23.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $4.51M.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $360.00K.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $23.70M, a 137.42% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $9.98M, a 1191.20% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $773.00K, a 89.70% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $7.50M, a 37.50% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $23.70M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $9.98M 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $773.00K 10-K · filed 2025-02-28 | |||
| 2022-12-31 | $7.50M 10-K · filed 2024-03-14 | |||
| 2021-12-31 | $12.01M 10-K · filed 2023-03-03 | |||
| 2020-12-31 | $3.31M 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.51M derived: sum of 2 quarters · filed 2021-03-01 | $4.51M derived: sum of 3 quarters · filed 2021-03-01 | $4.87M 10-K · filed 2021-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $360.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-05 | $360.00K 10-Q · filed 2019-08-05 | ||
| 2019-03-31 | $360.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |